Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DMAA Supplements Banned In U.K., Hamstrung In U.S.

This article was originally published in The Tan Sheet

Executive Summary

The Medicines and Healthcare products Regulatory Agency bans use of dimethylamylamine in the United Kingdom. Meanwhile, FDA has stopped short of an all-out ban, though retailers and insurance carriers largely have turned their backs on DMAA.

You may also be interested in...



Military Report Slams DMAA While GNC Claims Victory

A Department of Defense safety review panel does not find a conclusive causal association between DMAA and adverse events, including four service members’ deaths, a conclusion that “delighted” retailer GNC. But DoD’s ban on sales of DMAA products in military exchanges and concessions remains in place.

Military Report Slams DMAA While GNC Claims Victory

A Department of Defense safety review panel does not find a conclusive causal association between DMAA and adverse events, including four service members’ deaths, a conclusion that “delighted” retailer GNC. But DoD’s ban on sales of DMAA products in military exchanges and concessions remains in place.

FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door

USPlabs says it will reformulate its DMAA supplements, although it “stands by the safety and legality” of the products. FDA says “credible science” shows DMAA is not a botanical, not a dietary ingredient and will not be accepted in an NDI notification.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel